Regen BioPharma Reports Stable Revenue but Increased Losses and Operating Expenses for December 2025 Quarter

Regen BioPharma, Inc. reported its financial results for the quarter ending December 31, 2025, revealing a net revenue of $59,065, consistent with the same period in 2024. The revenue breakdown included $31,640 from general operations and $27,425 from related party transactions, specifically related to a licensing agreement with Zander Therapeutics, Inc. Despite stable revenue figures, the company experienced a significant increase in operating expenses, which rose to $610,689 from $120,443 in the prior year, primarily due to heightened research and development costs of $210,000 and general and administrative expenses of $231,925.

The company's net loss for the quarter was $967,853, a substantial increase from the $515,384 loss reported in the same quarter of the previous year. This increase in loss was attributed to the rise in operating expenses across all categories, excluding rent, which decreased. The loss from operations also escalated to $551,624 compared to $61,378 in the prior year, reflecting the company's ongoing investment in its development initiatives. The total other expenses, including interest and derivative liabilities, contributed to the overall net loss, although they showed a slight decrease from $454,007 in 2024 to $416,229 in 2025.

In terms of operational developments, Regen BioPharma has been actively pursuing its research agenda, particularly in regenerative medicine. The company is in the early stages of developing products aimed at immune cell activation for oncology and immune cell suppression for autoimmune diseases. As part of its strategic initiatives, Regen entered into consulting agreements with Dr. Harry Lander and its CEO, David Koos, compensating them with newly issued common shares contingent upon the successful completion of a planned Phase I clinical trial for HemaXellerate.

The company’s financial position remains precarious, with cash reserves dwindling to $4,578 and an accumulated deficit of approximately $22.7 million as of December 31, 2025. The working capital deficit increased by $291,814 during the quarter, primarily due to rising derivative liabilities. Regen BioPharma has indicated that it will need to secure additional funding through equity or debt offerings to continue its operations and development plans. The management has expressed significant doubt regarding the company's ability to continue as a going concern without such funding, highlighting the critical need for financial support to sustain its business activities in the coming months.